Sporasec is a brand of oral anti-fungal drug manufactured by Janssen-Cilag, a subsidiary of Johnson and Johnson. The active ingredients in Sporasec are itraconazole or secnidazole, and it is prescribed primarily to immunocompromised and non-immunocompromised patients for the treatment of fungal medical conditions, which include histoplasmosis, pulmonary and extrapulmonary blastomycosis, onychomycosis, cryptococcal meningitis and aspergillosis.
Itraconazole is also used for the treatment of fungal infections of the fingernails and toenails, and yeast infections for the mouth and throat. It belongs to a class of antifungals called triazoles and its main mechanism of action is to inhibit the growth and spread of fungi that causes the infection. Itraconazole should be taken with caution, as it is known to cause congestive heart failure.
Secnidazole, on the other hand, is a nitroimidazole anti-infective that has been reported to be effective for the treatment of amoebiasis, giardiasis, bacterial vaginosis and trichomonas. A single dose of secnidazole has a clinical and parasitological cure rate of 80 to 100 percent, and 92 to 100 percent cure rates in patients with urogenital trichomoniasis. Compared to itraconazole, secnidazole is well-tolerated and most of the ill effects reported from taking this drug are gastrointestinal in nature.
Sporasec is administered orally. Sporasec with itraconazole is available in 33.3 milligrams. and 166.6 milligrams with secnidazole.